Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LB-DTK-COV19 in Prolonged SARS-CoV-2 Infected Patients
NCT07690943Completed
- Sponsor
- LucasBio
- Start
- Jun 2023
- Primary completion
- May 2024
- Countries
- 1
01
Overview
Open-label, single-arm trial of LB-DTK-COV19 in coronavirus disease 2019 (COVID-19), sponsored by LucasBio. Primary endpoints: SARS-CoV-2 Viral load at 24 weeks, World Health Organization Ordinal Scale at 24 weeks and 5 more. Started Jun 2023; status: completed.
02
Drugs
LB-DTK-COV19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07690943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07690943.